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ABSTRACT
Intestinal homeostasis mechanismsmust protect the host intestinal tissue from endogenous lipopolysaccharides (LPSs) pro-
duced by the intestinal microbiota. In this report, we demonstrate that murine intestinal fecal lipids effectively block Toll-like
receptor 4 (TLR4) responses to naturally occurring Bacteroidetes sp. LPS. Cardiolipin (CL) represents a significant proportion of
the total intestinal and fecal lipids and, furthermore, potently antagonizes TLR4 activation by reducing LPS binding at the lipo-
polysaccharide binding protein (LBP), CD14, andMD-2 steps of the TLR4 signaling pathway. It is further demonstrated that
intestinal lipids and CL are less effective at neutralizing more potent Enterobacteriaceae-type LPS, which is enriched in feces ob-
tained frommice with dextran sodium sulfate (DSS)-treated inflammatory bowel disease. The selective inhibition of naturally
occurring LPS structures by intestinal lipids may represent a novel homeostasis mechanism that blocks LPS activation in re-
sponse to symbiotic but not dysbiotic microbial communities.
IMPORTANCE
The guts of animals harbor a variety of Gram-negative bacteria associated with both states of intestinal health and states of dis-
ease. Environmental factors, such as dietary habits, can drive the microbial composition of the host animal’s intestinal bacterial
community toward a more pathogenic state. Both beneficial and harmful Gram-negative bacteria are capable of eliciting poten-
tially damaging inflammatory responses from the host intestinal tissues via a lipopolysaccharide (LPS)-dependent pathway.
Physical mucosal barriers and antibodies produced by the intestinal immune system protect against the undesired inflammatory
effects of LPS, although it is unknown why some bacteria are more effective at overcoming the protective barriers than others.
This report describes the discovery of a lipid-type protective barrier in the intestine that reduces the deleterious effects of LPSs
from beneficial bacteria but is less effective in dampening the inflammatory effects of LPSs from harmful bacteria, providing a
novel mechanistic insight into inflammatory intestinal disorders.
The intestinal tract is constantly exposed to the potentiallyharmful effects of lipopolysaccharide (LPS), commonly re-
ferred to as endotoxin. Both internal sources, such as the intestinal
microbiome, and external sources, such as food, provide a con-
stant potential for endotoxin-mediated local or systemic injury.
Several different innate and adaptive protective mechanisms pres-
ent in the intestine facilitate a homeostatic relationship with the
resident commensal microbiota and buffer food intake such that
LPS does not impair normal intestinal tissue functions (1–5).
Studies have shown that a major mechanism by which the in-
testine limits exposure to the potentially harmful effects of LPS is
by preventing intestinal LPS-epithelial cell interactions through a
physiochemical barrier consisting of a family of glycoproteins re-
ferred to as mucins. Mucins provide an effective barricade restrict-
ing the ability of both commensal and pathogenic microbiota and
their respective bacterial components to gain access to the intes-
tinal epithelium, thereby limiting the magnitude of potential LPS
interactions with intestinal epithelial cells (6). In addition, LPS-
modifying enzymes produced in intestinal tissue can render the
LPS less toxic, reducing the potential for inappropriate inflamma-
tion (7, 8). Furthermore, host adaptive immune responses include
the production of IgA by plasma cells present in the intestinal
mucosa, and TH1- and TH17-mediated immunity (9) provides an
additional significant level of protection of the intestinal epithe-
lium from the resident microbiota. Other studies have presented
evidence that selective Toll-like receptor (TLR) expression and
epithelial cell polarization may hinder intestinal epithelial cell ex-
posure to LPS, preventing destructive inflammation (10).
However, the mechanisms by which the host protects intestinal
tissues from LPS exposure are impaired in certain forms of inflam-
matory bowel disease (IBD). For example, anti-TLR4 antibodies
have been shown to reduce intestinal damage in dextran sodium
sulfate (DSS)-treated mice (11), consistent with a significant in-
crease in water-soluble pattern recognition receptor ligands in the
feces of DSS-treated mice, such as the LPS receptor TLR4 (12).
Similarly, in humans, individuals with Crohn’s disease have in-
creased circulating levels of MD-2, a key LPS coreceptor for TLR4
which results in significantly increased TLR4-dependent intestinal
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epithelial cell responses in vitro (13). In addition, evidence sug-
gesting that LPS exposure is involved in acute-phase responses in
both Crohn’s disease and experimental murine colitis has been
presented (14). Furthermore, a high-fat diet also results in intes-
tinal epithelial cell exposure to elevated levels of LPS, altering the
permeability of intestinal epithelial cells by a TLR4-dependent
mechanism, contributing to metabolic syndrome (15–17).
These findings of LPS-associated intestinal abnormalities
stand in stark contrast to the findings of studies which have shown
that orally administered LPS interacts with intestinal tissue and
contributes to the maintenance of a healthy homeostatic relation-
ship (18–20). One rationale for this apparent contradiction is the
observation that intestinal dysbiotic communities alter normal
intestinal homeostatic mechanisms. A common theme found in
intestinal dysbiotic communities is a significant increase in the
proportion of members of the family Enterobacteriaceae (15, 21–
23). This change in microbial community composition signifi-
cantly alters the amount and type of LPS to which intestinal tissue
is exposed. In fact, it was recently demonstrated in a mouse model
system that Rag1/ mice harboring a high proportion of isolates
of the family Enterobacteriaceae developed colitis (24). However,
little is known concerning how the host may regulate LPS expo-
sure to intestinal tissue in order to accomplish intestinal homeo-
stasis and how LPS exposure is detrimental and associated with
destructive inflammatory disease.
In this report, a novel mechanism by which the host selectively
suppresses LPS activation in the intestinal tract is described. It was
found that cardiolipin (CL), which is normally present in feces as
a result of intestinal epithelial cell turnover, blocked TLR4 re-
sponses to LPS. Furthermore, LPS isolated from mouse feces
containing normal intestinal microbiota or from Bacteroides
thetaiotaomicron, a human intestinal symbiont, was more effec-
tively neutralized than LPS obtained from the feces of DSS-treated
mice or Escherichia coli, a bacterium found to be present in in-
creased proportions in patients with IBD. These observations are
consistent with the notion that alterations in the LPS composition
arising from modulations in the Gram-negative microbial com-
munity can overwhelm the lipid antagonist barrier, contributing
to the progression of intestinal dysbiosis-related diseases.
MATERIALS AND METHODS
Mouse strains and animal maintenance. All animal experiments de-
scribed in this report were performed after review and approval by both
the Queen Mary University of London and the University of Washington
Institutional Animal Care and Use Committees, which exceed the guide-
lines required by the NIH for funding. All animal experiments were con-
ducted in accredited facilities in accordance with the United Kingdom
Animals (Scientific Procedures) Act 1986 (Home Office license number
7006844). Germfree (GF) C3H/He mice were maintained in sterile isola-
tors at the Royal Veterinary College, University of London. Germfree
status was confirmed by aerobic and anaerobic culture of oral swabs and
fecal pellets on nonselective media and by PCR using universal 16S rRNA-
specific primers. Specific-pathogen-free (SPF) C3H/He mice were main-
tained in individually ventilated cages at the biological service unit of
Queen Mary University of London.
Isolation of bacterial LPS and mouse fecal LPS. Purified E. coli LPS
(EcLPS) was purchased from Sigma Chemical Co. (St. Louis, MO). B.
thetaiotaomicron LPS (BtLPS), SPF mouse fecal LPS, GF mouse fecal LPS,
and DSS-treated mouse fecal LPS were isolated by the Tri-reagent extrac-
tion procedure as previously described (25, 26). The SPF mouse fecal LPS
extract, which is based upon the starting dry weight of the fecal sample,
was observed to contain a minimum of 50 ng LPS/mg total extract, trans-
lating to approximately 5 ng/ml in crude fecal LPS (100 g/ml) aqueous
extracts, as determined by a Limulus amebocyte lysate (LAL) assay using
BtLPS standards (data not shown).
Total lipid extraction from GF and SPF mouse feces. The chloro-
form-methanol-based extraction procedure used for isolation of the lipid
fractions from both GF and SPF mouse feces was performed as described
previously (27) with modifications which avoided the use of water as an
extraction component. Briefly, GF mouse feces (3.4 g) were resuspended
in 40 to 50 ml of deionized water, and the suspension was lyophilized.
Freeze-dried GF mouse feces (600 mg) were resuspended in 35 to 40 ml of
a mixture of chloroform-methanol (1:1, vol/vol), and extraction was car-
ried out under vigorous stirring for 1 to 1.5 h at room temperature. Insol-
uble debris was removed from the resulting suspension by filtration
through cotton wool. The excess of the organic solvent was removed in
vacuo, and the dried residue was reconstituted by adding 2.5 to 3 ml of
methanol. The resulting suspension was filtered using an Acrodisc LC
polyvinylidene difluoride (PVDF) filter membrane (diameter, 25 mm;
pore size, 0.45 m; Gelman, United Kingdom). Excess methanol was
removed under a stream of oxygen-free nitrogen to yield 46 mg of the
crude lipid fraction, which was stored at20°C for either further analysis
or a second round of purification.
Total lipid extraction from SPF and GF mouse intestinal mucosa
and intestinal contents. Samples of intestinal mucosa and the intestinal
(ileum) contents from both SPF and GF mice were collected, and each
sample was suspended in 1.5 ml of deionized water, followed by freeze-
drying. Each freeze-dried sample was weighed, transferred into a 4-ml
glass screw-top vial, and resuspended in 1.5 ml of a mixture of chloro-
form-methanol (1:1, vol/vol). Extraction of the lipid components was
carried out as described above for the total lipid extraction of the mouse
feces. After extraction, insoluble debris was removed from each sample by
passing the suspension through a cotton wool filter, and the samples were
dried under a stream of oxygen-free nitrogen. The solid residue in each
sample was resuspended in 0.5 ml of methanol (MeOH), the insoluble
material was removed by final filtration using the Acrodisc LC PVDF filter
membrane and dried as described above, and the dried samples were
stored at20°C for further analysis.
Quantitative analysis of CL in SPFfeccm, GFfeccm, GFimcm,
SPFimcm, and DSSfecd1–d7 cm. Quantitative analysis of the cardiolipin
(CL) in chloroform-methanol lipid extracts of the feces of SPF mice (SPF-
feccm) and GF mice (GFfeccm), chloroform-methanol lipid extracts of the
intestinal mucosa (ileum) of SPF mice (SPFimcm) and GF mice (GFimcm),
and chloroform-methanol lipid extracts of the feces of DSS-treated mice
after 1 day of treatment (DSSfecd1 cm) and 7 days of treatment (DSSfecd7 cm)
was carried out using a modified protocol for fluorometric determination
of CL described previously (28, 29). For each fluorometric determination
of the CL species in the fecal lipid extracts, duplicate dilutions of a stock
solution of CL (bovine heart CL, sodium salt; Sigma-Aldrich) in methanol
(3.3 mM) were prepared over a concentration range of from 0 to 2.5 mM
on each 96-well microtiter plate (F96 Microwell black polystyrene micro-
plate; Thermo Scientific, Denmark) to generate a calibration curve. To
generate the calibration curves and determine the CL contents of the fecal
and mucosal lipid extracts in the CL binding assay, 50 l of CL standard
solutions in methanol and 50l of duplicate solutions of extracts in meth-
anol (50 g to 200 g) were added to 96-well microtiter plates, followed
by evaporation of the organic solvent overnight at 4°C. Fifty microliters of
a 4 mM solution of 10-N-nonyl-acridine orange (NAO; Biotium, Cam-
bridge Biosciences, United Kingdom) in methanol-water (1:1, vol/vol)
was added to each well, and the microtiter plate was incubated at room
temperature in the dark for 30 min. Nonbound NAO was removed by
washing the wells three times with a solution of phosphate-buffered saline
(PBS) in methanol-water (1:1, vol/vol). Fluorescence was detected by use
of a fluorescence model SIAFR Synergy HT microplate reader (Bio-Tek
Instruments [USA]) using two filter sets, as follows: filter set 1 had an
excitation  of 485/20 nm and an emission  of 528/20 nm, and filter set 2
had an excitation  of 485/20 nm and an emission  of 590/35 nm. The
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data were acquired and processed using KC4 Bio-Tek software (v.3.4).
The concentrations of the CL species in the lipid extracts were determined
from the bovine heart CL standard curves by linear interpolation of the
fluorescence intensity as a function of the molar concentrations of CL and
expressed as the amount of CL (in milligrams) per milligram of the lipid
extract. Based upon determination of the CL concentrations from extracts
derived from the dry weight of the intestinal contents (n 6) and assum-
ing that the dry weight was approximately 20% of the wet weight, we
estimated that the mean concentration of CL in the intestinal lumen was
as high as 5 mg/ml, which exceeded the amounts of CL employed in the in
vitro assays of this study that were sufficient for BtLPS inhibition (1 to 100
g/ml).
Model of DSS treatment and determination of bacterial contents in
DSS-treated mice. DSS (molecular weight, 40,000; Sigma-Aldrich) was
prepared fresh daily by dissolving DSS in ultrapure water and adjusting
the final pH to 8.5. Female mice (age, 8 weeks; weight, 20 to 23 g) received
5% (wt/vol) DSS ad libitum for 7 days. Healthy age-matched controls
received ultrapure water only. A disease activity index was derived from
the major clinical signs of weight loss, diarrhea, and rectal bleeding as
described by Murthy et al. (30).
The mice were weighed daily, and feces from the DSS-treated and
control groups were collected and pooled daily. At the end of the experi-
ment, the animals were euthanized by carbon dioxide asphyxiation. In-
testines and colons were opened longitudinally, and the contents were
collected. Open intestines were rinsed in ice-cold PBS and placed on a
clean glass surface, and the intestinal mucosa was scraped off with a clean
glass slide.
Intestines and colon contents (10 mg) were suspended in sterile re-
duced transport medium for serial dilution. Blood agar plates containing
5% defibrinated horse blood were seeded and incubated for 3 days in an
anaerobic atmosphere of 80% N2, 10% H2, and 10% CO2 (Don Whitely
Scientific). Colonies were counted to determine the number of CFU per
gram, pure cultures of bacteria were obtained, and the bacteria were iden-
tified by 16S rRNA sequencing.
MALDI-TOF MS analyses of fecal and intestinal lipids. For matrix-
assisted laser desorption ionization–time of flight (MALDI-TOF) mass
spectrometry (MS) analyses, total fecal lipid samples were dissolved in 10
l of a mixture of 5-chloro-2-mercaptobenzothiazole (20 mg/ml) in chlo-
roform-methanol (1:1, vol/vol), and 0.5l of each sample was analyzed in
both positive and negative ion modes on an AutoFlex analyzer (Bruker
Daltonics). Data were acquired with a 50-Hz repletion rate, and up to
3,000 shots were accumulated for each spectrum. Instrument calibration
and all other tuning parameters were optimized using an HP Calmix
(Sigma-Aldrich, St. Louis, MO). Data were acquired and processed using
flexAnalysis software (Bruker Daltonics).
Gel permeation chromatography and HPLC. The total chloroform-
methanol lipid extract from either GF or SPF mouse feces was dissolved in
1.5 ml of MeOH, followed by gel permeation chromatography on a Toyo-
Pearl HW-40 (S) column (35 cm by 2 cm [inside diameter {i.d.}]); Tosoh,
Anachem Ltd., United Kingdom) equilibrated with the same solvent. The
column effluent was monitored for changes in the refractive index (RI)
with a Knauer Wellchrom K-2400 RI detector (Wissenschaftliche Gerate-
bau, Dr. Ing. Herbert Knauer GmbH, Berlin, Germany). Peak fractions
(1.5 ml) were pooled, and an excess of the solvent was removed by a
stream of oxygen-free nitrogen. Each peak fraction was tested for biolog-
ical activity, and those fractions showing TLR4-inhibitory properties were
used for further purification. The high-molecular-weight lipid fraction,
which was isolated by gel permeation chromatography and which showed
potent inhibition of BtLPS-dependent TLR4 activation, was subjected to
another round of fractionation on a Glyco-Pac N column (7.8 mm by 300
mm [i.d.]; Waters, USA) in MeOH using a Beckman Coulter high-perfor-
mance liquid chromatography (HPLC) system (32 Karat software, v.7).
The column effluent was monitored for changes in RI as described above.
Fraction peaks were collected, the excess solvent was removed by a stream
of nitrogen, and the high-molecular-weight fractions, which showed
TLR4-inhibitory activity, were pooled. The high-molecular-weight frac-
tion obtained from the fractionation of GFfeccm was referred to as fraction
1 and used for further analysis.
Acidic methanolysis of lipid fraction samples. Fatty acids from the
lipid fraction samples were liberated by acid-catalyzed methanolysis as
described previously (31). Briefly, 3 N methanolic HCl (300 l; Supelco,
USA) was added to the dried sample (2 to 3 mg), which was placed in a
glass screw-top vial (4 ml) with a perforated (open-top, silicone septum)
screw cap, and the reaction mixture was heated at 85°C for 12 h. Samples
for subsequent analysis by gas chromatography (GC)-MS were extracted
into 0.5 ml hexane, excess solvent was removed by a stream of oxygen-free
nitrogen, and the samples were kept dried.
Fatty acid composition. Analysis of the composition of the fatty acids
present in the lipid fractions was carried out by GC-MS using a 6890N
Network GC system and a 5975 inert mass-selective detector (Agilent
Technologies, United Kingdom) equipped with a Sepelcowax 10 capillary
column (30 m by 0.25 mm [i.d.]; film thickness [df], 0.25 m; Sepelco-
wax, United Kingdom). Analysis of the fatty acid methyl esters was carried
out by acid methanolysis of the samples, followed by dissolution of the
methanolysate in 250 ml of hexane; 1 ml of this solution was used for
GC-MS analysis. The injector temperature was set to 60°C, and the fol-
lowing temperature gradient was used: 60°C for 3 min, followed by an
increment of 10°C/min up to 140°C and 2°C/min up to 230°C, where the
sample was maintained for 10 min. Helium was used as a carrier gas at a
flow rate of 1.0 ml/min. The analytes were ionized in the positive ion mode
by electron impact (EI) at 70 eV. The spectra were collected over the m/z
50 to m/z 500 range, and extracted ion chromatograms were analyzed by
searching the spectral library NIST standard reference database 1A (NIST
05; NIST, Gaithersburg, MD, USA). The ratios of the fatty acid methyl
esters in the analytes were calculated on the basis of the integration of the
area under the peaks of interest using the diagnostic fragment ion species
at m/z 74 and m/z 87. The molecular masses of the polyunsaturated fatty
acids were estimated according to the values of characteristic fragment
ions m/z [M-31].
Fatty acid analysis of the high-molecular-weight fraction (fraction 1),
which was obtained after chromatography of GFfeccm on a ToyoPearl
HW-40 (S) column, revealed the presence of four major fatty acids, which
were found to be hexadecanoic acid (C16:0), 14-methylpentadecanoic acid
(iso-C16:0), monounsaturated 9-octadecenoic acid (C18:1, oleic acid), and
diunsaturated 9,12-octadecadienoic acid (C18:2, linoleic acid), which were
present in a molar ratio of 3.8:1:3.8:3 (see Table S1 in the supplemental
material). In addition, traces of octadecanoic acid (C18:0) were detected.
NMR spectroscopy. Deuterium exchange of lipid fractions was car-
ried out by repeated dissolution of the sample in CD3OD (99.90% deute-
rium; Sigma-Aldrich) and drying of the sample under a stream of oxygen-
free nitrogen. Finally, the lipid fraction sample was dissolved in 0.60 ml of
CD3OD (99.90% deuterium; Sigma-Aldrich). Acetone was used as an
internal standard (H 2.225). The one-dimensional
1H nuclear magnetic
resonance (NMR) spectrum was recorded at 25°C on a Bruker AV400
spectrometer. Data were acquired and processed using Bruker TOPSPIN
(v.2) software.
Analysis of the 1H NMR spectral data for fraction 1 (Table 1; see also
Fig. S2B in the supplemental material) revealed the presence of signals for
protons at 4.29 ppm and in the region from 5.0 to 5.10 ppm. The signal at
4.29 ppm corresponds to protons linked at C-1, and the signal in the
region from 5.0 to 5.10 ppm corresponds to protons linked at glycerol C-2
side chain residues. These are the glycerol carbons linked to fatty acids R1
to R4 in Fig. 4E (32).
Signals in the 1H NMR spectrum at 4.00 ppm and 4.05 ppm were
assigned to the protons at position C-3 of the side chain glycerol residues
which are phosphorylated at position O-3 (Table 1; see also Fig. S2B in the
supplemental material). The group of signals for protons with different
intensities in the region from 3.70 to 3.90 ppm is indicative of H=1-H=3 of
the central glycerol residue, therefore confirming the identity of this over-
all molecular species to be a CL entity (33).
Coats et al.
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1H NMR spectrum of fraction 1 also revealed the presence of signals
for protons of both saturated and unsaturated fatty acid residues (see Fig.
S2A and Table S2 in the supplemental material). The comparison of the
intensities of the proton signals at 2.14 ppm and 2.68 ppm, which corre-
sponded to -methylene protons of all fatty acid residues and bisallylic
protons of linoleic acid, respectively (34), gave a ratio value of 4:1. These
data are in accordance with the ratio of fatty acids estimated by GC-MS-
based quantitative analysis of fatty acids of fraction 1 (see Table S1 in the
supplemental material).
TLR4 reporter assays for LPS activation and LPS antagonism.
HEK293 cell-based TLR4 reporter assays were performed essentially as
described previously (35). Briefly, HEK293 cells were plated in 96-well
plates at a density of 4	 104 cells per well and on the following day were
transfected with plasmids bearing firefly luciferase, Renilla luciferase, hu-
man TLR4, and MD-2 by standard calcium phosphate precipitation. The
test wells were stimulated in triplicate for 4 h at 37°C with the doses of LPS
indicated below that had been combined with fecal lipids, frozen at20°C
overnight, and subsequently thawed and suspended in Dulbecco modified
Eagle medium containing 10% fetal bovine serum to achieve the final
stimulatory concentrations. Following stimulation of the TLR4-trans-
fected HEK293 cells, the cells were rinsed with phosphate-buffered saline
and lysed with 50 l of passive lysis buffer (Promega, Madison, WI).
Luciferase activity was measured using a dual-luciferase assay reporter
system (Promega, Madison, WI). Data are expressed as the fold increase of
NF-
B activity, which represents the ratio of NF-
B-dependent firefly
luciferase activity to-actin promoter-dependent Renilla luciferase activ-
ity. Where indicated in the figure legends, data were analyzed by two-
tailed unpaired Student t tests (GraphPad Prism).
LBP, CD14, and MD-2 binding assays. The supernatants that were
used in the binding assays were generated as follows: HEK293T cells were
plated in 10-cm plates, grown to approximately 60% confluence, and
transfected with 20 g of plasmids carrying the soluble MD-2 (MD-2)
with a 6	His tag, soluble lipopolysaccharide binding protein (LBP) with
a 6	His tag, or soluble CD14 (CD14) with a 6	His tag by the calcium
phosphate method for 2 to 4 h. Subsequently, the transfection complexes
were removed, 10 ml of fresh growth medium was added per plate, and the
cells were cultured for 2 days prior to harvesting of the supernatants.
Binding assays were performed essentially according to the method of
Visintin et al. (36), as follows: for each binding reaction, biotinylated
EcLPS and fecal lipid antagonists were combined and frozen at 20°C
overnight. The LPS-antagonist complexes were then resuspended in 4 ml
of recombinant protein supernatant at the doses indicated below and in
the figure legends. LPS-antagonist-protein interactions were allowed to
form by incubation for 3 to 4 h at 21°C. The LPS-LBP-6	His, LPS-CD14-
6	His, and LPS–MD-2– 6	His complexes were all captured by addition
of 40 l (packed volume) streptavidin-agarose beads (Sigma-Aldrich, St.
Louis, MO) to 4 ml supernatant, followed by agitation overnight on a
rotator at 4°C. The agarose beads were pelleted by centrifugation for 30 s
at 8,000	 g and 4°C. The beads were washed three times with PBS (LBP
and CD14 complexes) or PBS containing 0.5% Tween 20 (MD-2 com-
plexes). The washed beads were then resuspended in SDS sample buffer
(Invitrogen, Carlsbad, CA), and the proteins in the sample were resolved
in nonreducing, denaturing 4% to 20% Tris-glycine polyacrylamide gels
(Invitrogen, Carlsbad, CA) and then transferred to a PVDF membrane
(Invitrogen, Carlsbad, CA). The membranes were probed overnight at
4°C using a monoclonal anti-tetra-His antibody (Qiagen, Valencia, CA).
The blot was washed and probed with goat anti-mouse IgG antibody-
horseradish peroxidase conjugate (Jackson ImmunoResearch Laborato-
ries, West Grove, PA) for 1 h at room temperature. Detection of the
proteins was achieved by treating the blots with SuperSignal West Pico
chemiluminescent substrate (Pierce, Rockford, IL) followed by exposure
to BioMax MS film (Kodak).
RESULTS
LPS activation is suppressed in themouse gastrointestinal tract.
The gastrointestinal tract is exposed to LPS from both endogenous
sources, such as the intestinal microbiota, and exogenous sources,
such as LPS found in the diet (37). Therefore, we determined if
LPS was able to elicit TLR4 activation during passage through the
intestinal tract and incorporation in the feces. To accomplish this,
intestinal and colon contents as well as feces were suspended in
endotoxin-free water, and the ability of these aqueous suspensions
to activate TLR4 in an HEK293 cell-based TLR4- and MD-2-me-
diated NF-
B activation assay was compared to that of crude LPS
preparations obtained from the same samples. For these compar-
isons, crude LPS was extracted and resuspended in the same vol-
ume as the original intestinal sample, such that the same LPS
concentration was examined in both extracted and nonextracted
samples (Fig. 1). We observed that the fecal LPS aqueous extract
(100g/ml) from SPF mice contained a minimum LPS content (5
ng/ml), as determined by an LAL assay (data not shown).
In SPF mice, where both the endogenous microbiota and di-
etary intake can contribute to LPS in the intestinal tract, compar-
ison of aqueous extracts to the corresponding LPS extracts re-
vealed that the fecal or colon contents displayed significantly
lower levels of TLR4 activation, demonstrating that the colon and
fecal contents suppress TLR4 activation (Fig. 1A and B). In con-
trast, there was no significant difference in the ability of the intes-
tinal aqueous or crude LPS preparation to elicit a TLR4 response
(Fig. 1C). The lack of a significant difference in TLR4 activation
between intestinal aqueous and crude LPS preparations was fur-
ther examined. First, it was determined that the number of bacte-
ria found in the intestine was at least 2 log units lower than that
found in the colon or feces (compare the results with those for the
control in Fig. 7A and B [see below]). Second, aqueous suspen-
sions of the SPF and GF mouse diets were tested in the TLR4
HEK293 cell-based assay, and the results revealed that the ability
of the SPF mouse chow to activate TLR4 (see Fig. S1 in the sup-
TABLE 1 1H NMR spectral data for purified lipid extract of feces from GF micea
Residue H (ppm) Vicinal coupling (
3JH,H) Reference chemical shift
b
Side chain glycerol residues acylated with glycerol
fatty acids R1 to R4
c
CH2OR1(4) 4.29 JH1b,H2  6.7 Hz, JH1b,H1a  12.1 Hz 4.36
CHOR2(3) 5.0–5.10 5.15
CH2OP(O) 4.00, 4.05 JH3a,H2  6.2 Hz, JH3a,H3b  10.4 Hz 3.92
Central residue POCH2CH(OH)CH2OP 3.70–3.90 3.84–3.93
a The data are for fraction 1 and were obtained on a ToyoPearl HW-40 (S) column. The protons of the glycerol side chains and the glycerol moiety are indicated in italic.
b The reference chemical shifts are described elsewhere (33).
c See Fig. 4E.
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plemental material) was at least a 5-fold less than that of the GF
mouse chow. Therefore, the lack of a sufficient number of bacteria
combined with the low TLR4 activity found in SPF mouse chow
but not GF mouse chow may have precluded the detection of LPS
activation in the crude LPS preparations due to the sensitivity of
our assay. In GF mice, where only the effect of dietary LPS was
examined, all three components of the intestinal tract examined
displayed a significantly lower ability to activate TLR4 than their
corresponding LPS preparations (Fig. 1D to F). These data dem-
onstrate that in GF mice the contents of all three components of
the gastrointestinal tract examined demonstrate potent suppres-
sion of TLR4 activation.
Therefore, LPS activation of TLR4 from either endogenous
sources, such as the intestinal microbiota, or exogenous sources,
such as the GF mouse diet, is suppressed during transit through
the gastrointestinal tract.
Total lipid extracts derived frommouse feces specifically in-
hibit LPS-dependent TLR4 proinflammatory responses. It has
been reported that host phospholipids can inhibit LPS activation
(38). Therefore, we tested the possibility that phospholipids pres-
ent in mouse feces (39) contributed to the inhibition of TLR4. A
chloroform-methanol-based extraction procedure was employed
to obtain the total lipid fraction from both SPF and GF mouse
feces (27). The chloroform-methanol lipid fractions were then
examined for their ability to inhibit TLR4 activation in response to
the crude fecal LPS preparations obtained from SPF and GF
mouse feces described above (Fig. 2A and B). The chloroform-
methanol preparations obtained from both SPF and GF mouse
feces significantly antagonized the activation of TLR4 signaling by
the fecal LPS preparations in a dose-dependent manner. Further-
more, the chloroform-methanol preparations did not inhibit the
closely related interleukin-1 (IL-1) receptor (IL-1R)-dependent
FIG 1 The gastrointestinal contents of both SPF mice and GF mice contain activity inhibiting TLR4 activation by gastrointestinal lipopolysaccharides.
Recombinant TLR4 activity was measured using a HEK293 cell-based luciferase reporter assay. (A) The relative abilities of SPF mouse feces (SPFfec) or LPS
extracts from SPF mouse feces (SPFfecLPS) to activate TLR4 were compared. (B) The relative abilities of SPF mouse colon contents (SPFcc) or LPS extracts from
SPF mouse colon contents (SPFccLPS) to activate TLR4 were compared. (C) The relative abilities of SPF mouse intestinal contents (SPFic) or LPS extracts from
SPF mouse intestinal contents (SPFicLPS) to activate TLR4 were compared. (D) The relative abilities of GF mouse feces (GFfec) or LPS extracts from GF mouse
feces (GFfecLPS) to activate TLR4 were compared. (E) The relative abilities of GF mouse colon contents (GFcc) or LPS extracts from GF mouse colon contents
(GFccLPS) to activate TLR4 were compared. (F) The relative abilities of GF mouse intestinal contents (GFic) or LPS extracts from GF mouse intestinal contents
(GFicLPS) to activate TLR4 were compared. The results are representative of those from at least two independent experiments and are plotted as the mean fold
induction  standard deviation from triplicate determinations relative to that for the unstimulated control. hTLR4, human TLR4; hMD-2, human MD-2.
Asterisks represent significant differences in NF-
B activation elicited by the sample and derivative LPSs, as indicated by the dashed lines (*, P 0.05; **, P
0.001; ***, P 0.0001; ns, not significant; unpaired Student t tests).
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NF-
B activation pathway at the highest concentration of the fecal
lipid extracts tested (100g/ml) (Fig. 2C), demonstrating that the
inhibition of TLR4 activation was specific for LPS in the HEK293
cell-based assay.
Lipids derived from feces and the host intestinal mucosa an-
tagonize Bacteroides thetaiotaomicron LPS-dependent TLR4
activation. The ability of the fecal chloroform-methanol prepara-
tions described above as well as intestinal chloroform-methanol
preparations to suppress TLR4 activation in response to a purified
B. thetaiotaomicron LPS preparation was determined. LPS puri-
fied from B. thetaiotaomicron was employed as a representative
LPS found in the intestines of healthy mice (35). Similar to the
findings obtained with the crude fecal LPS preparations, TLR4
activation in response to B. thetaiotaomicron LPS was significantly
suppressed in a dose-dependent manner by the fecal chloroform-
methanol preparations obtained from either SPF mouse feces
(Fig. 3A) or GF mouse feces (Fig. 3B). Next the ability of chloro-
form methanol extracts obtained from the intestinal mucosa (il-
eum) to suppress TLR4 responses to B. thetaiotaomicron LPS was
examined (Fig. 3). Chloroform-methanol extracts of the GF and
SPF mouse intestinal mucosa (colon plus intestine) were obtained
by the same procedure used to isolate fecal lipids. It was found that
lipid extracts obtained from both the SPF and GF mouse mucosa
were potent inhibitors of TLR4 activation in response to B.
thetaiotaomicron LPS (Fig. 3C and D, respectively). Collectively,
these data demonstrate that the feces as well as the intestinal mu-
cosa contain lipids that block the ability ofB. thetaiotaomicronLPS
to activate TLR4.
CL is a major fecal and intestinal lipid LPS antagonist.
MALDI-TOF MS was performed to identify the major mass ion
structures present in the fecal and intestinal mucosal chloroform-
methanol extracts of the GF and SPF mice (Fig. 4). A major cluster
containing prominent ions at m/z 1,423 and m/z 1,451 was con-
sistently identified to be the predominant structure found in chlo-
roform-methanol extracts obtained from SPF or GF mouse feces
as well as SPF or GF mouse intestinal mucosa (Fig. 4A to D). These
ions correspond to CL species. Additionally, GC-MS analysis
demonstrated the presence of a range of fatty acids which varied in
chain length and degree of saturation, i.e., from C16:0 to C18:1 and
C18:2 (see Table S1 in the supplemental material).
1H NMR char-
acterization (see Fig. S2A and B in the supplemental material) of
the chloroform-methanol extract obtained from GF mouse feces
confirmed the presence of fatty acids (see Table S2 in the supple-
mental material). Moreover, this 1H NMR spectrum also con-
tained signals for glycerol side chains and central glycerol moi-
eties, the positions of which are specific for CL (Table 1). On the
basis of these data, we propose that a major component of both
fecal and intestinal lipid extracts corresponds to different CL iso-
form structures with various degrees of fatty acid substitutions
(Fig. 4E). Consistent with CL representing the major mass ions
found in the MALDI-TOF MS analysis, quantitative analysis of
the CL content by a fluorometric assay using 10-N-nonyl-acridine
orange (NAO) demonstrated that CL constituted between 9% and
28% of the total mass of lipid extracts of the feces and intestinal
mucosa of both germfree and SPF mice, providing compelling
evidence that this phospholipid is a major constituent of intestinal
lipids (see Fig. S3 in the supplemental material). Assuming that
the dry weight of the intestinal contents is approximately 20%
of the wet weight, we estimate that the CL content in the contents
of the intestinal lumen may approach 5 mg/ml.
CL has previously been shown to inhibit tumor necrosis factor
alpha production from mononuclear cells in response to LPS,
most likely by inhibition of LPS interactions with lipopolysaccha-
ride binding protein (LBP) (38), a protein that contributes to sig-
nificantly increasing the sensitivity of TLR4 to LPS (40). There-
fore, the ability of commercially obtained, purified CL to inhibit
TLR4 activation in response to both LPS and IL-1 was deter-
mined in the HEK293 cell-based NF-
B assay (Fig. 5). CL specif-
ically inhibited B. thetaiotaomicron LPS-mediated TLR4 activa-
tion (Fig. 5A), while it failed to inhibit IL-1-dependent NF-
B
activation (Fig. 5B). These findings are consistent with CL being a
major TLR4 antagonist in the chloroform-methanol extracts.
Further evidence that CL represented the major component in
the chloroform-methanol extracts that inhibits TLR4 responses to
LPS was obtained by elucidating the molecular mechanism of fecal
FIG 2 The lipid fractions from SPF and GF mouse feces contain a substance
that specifically inhibits feces-derived LPS-dependent TLR4 activation. Re-
combinant TLR4 or endogenous IL-1R activity was measured using a HEK293
cell-based luciferase reporter assay. (A) Chloroform-methanol lipid extracts
from SPF mouse feces (SPFfeccm) inhibit SPF feces-derived LPS-dependent
TLR4 activation. (B) Chloroform-methanol lipid extracts from GF mouse fe-
ces (GFfeccm) inhibit GF mouse feces-derived LPS-dependent TLR4 activa-
tion. (C) Chloroform-methanol lipid extracts from either SPF mouse feces or
GF mouse feces do not inhibit IL-1-dependent IL-1R activation. The results
obtained with an agonist (LPS or IL-1) combined with SPFfeccm or GFfeccm
are representative of those from at least two independent experiments and
were plotted as percent activation minus the background standard deviation
from triplicate determinations relative to that for the agonist alone (LPS or
IL-1) minus the background, which was assigned a value of 100% activation.
Asterisks represent significant differences in NF-
B activation observed for
LPS alone compared to that observed for LPS in combination with the lipid
fraction (*, P  0.05; **, P  0.001; ns, not significant; unpaired Student
t tests).
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lipid LPS antagonism (Fig. 5C). A highly specific binding assay
which utilizes recombinant sLBP, sCD14, and sMD-2 was em-
ployed. The basis for this assay depends upon the ability of the LPS
antagonist to compete for binding at sLBP, sCD14, or sMD-2 with
a biotinylated E. coli LPS preparation (41). A reduction in the
signal intensity of autoradiogram images corresponding to LBP,
CD14, or MD-2 detected by Western blotting indicates the spe-
cific step at which antagonism occurs. Figures 5C and D depict the
results of the binding assay when chloroform-methanol extracts
obtained from GF and SPF mouse feces were examined. It was
found that purified CL was similar to chloroform-methanol ex-
tracts of SPF and GF mouse feces, in that antagonism against E.
coli LPS was observed at each step in the activation pathway, LBP,
CD14, and MD-2 (Fig. 5C). In contrast, the LPS antagonist de-
rived from the oral pathogen Porphyromonas gingivalis, which was
included as a comparative control for lipid A-type antagonism,
blocked E. coli LPS binding exclusively at the TLR4 coreceptor,
MD-2 (Fig. 5D), consistent with our previous results (25, 41).
These data demonstrate that the intestinal lipids present in SPF
and GF mouse feces mediate antagonism against E. coli LPS by a
mechanism that is distinct from the mechanism displayed by the
lipid A-type antagonistP. gingivalis LPS and is consistent with that
observed with purified CL.
Feces from DSS-treated mice exhibit a pronounced increase
in TLR4 activation. Inflammatory bowel disease has been asso-
ciated with an increase in TLR4 activation (11), and therefore,
we determined if feces from an IBD mouse model were altered
in their capacity to activate TLR4 (Fig. 6A). IBD was induced in
dextran sodium sulfate (DSS)-treated mice, an experimental
model commonly utilized to explore the molecular and cellular
mechanisms of IBD-related ulcerative colitis and colorectal
cancer (42). Initially, TLR4 activation by feces obtained from
conventionally fed mice was compared to that by feces ob-
tained from mice that were administered DSS daily from 1 to 7
days of treatment. These data revealed that after 5 days of DSS
administration, when the mice began to show signs of IBD by
the disease activity index (see Fig. S4 and S5 in the supplemen-
tal material), the feces displayed significant TLR4 activation
(Fig. 6A). In contrast, similar to what we described above,
TLR4 activation was suppressed in feces obtained from control
SPF mice not treated with DSS and presymptomatic DSS-
treated mice (up to day 4).
The significant increase in the TLR4 activity of feces from DSS-
treated mice obtained on day 7 of treatment (Fig. 6A) suggests that
the potency of the endogenous LPS had been altered relative to
that of the LPS in normal feces. To test this possibility, crude LPS
preparations were prepared from extracts of feces obtained from
DSS-treated mice on day 7 of treatment, and the TLR4 activity was
compared to that of LPS preparations from control SPF mouse
feces (Fig. 6B). These analyses revealed that the LPS preparation
from the feces of DSS-treated mice obtained on day 7 of treatment
resulted in significantly more potent TLR4 activity (approxi-
mately 4-fold) than control LPS preparations from the feces of
SPF mice.
In addition, chloroform-methanol extracts were generated
from feces collected from DSS-treated mice on day 1 to day 7 of
treatment to determine if the onset of IBD also correlated with the
loss of CL and the subsequent loss of TLR4-suppressing activity.
However, it was found that the CL content of the feces obtained
from DSS-treated mice on day 1 to day 7 of treatment did not
FIG 3 The lipid fractions from SPF and GF mouse feces and intestinal mucosa contain a substance that potently inhibits BtLPS-dependent TLR4 activation.
Recombinant TLR4 activity was measured using a HEK293 cell-based luciferase reporter assay. (A) Chloroform-methanol lipid extracts of feces from SPF mice
(SPFfeccm) inhibit BtLPS-dependent TLR4 activation. (B) Chloroform-methanol lipid extracts of feces from GF mice (GFfeccm) inhibit BtLPS-dependent TLR4
activation. (C) Lipid extracts from SPF mouse intestinal mucosa (SPFimcm) inhibit BtLPS-dependent TLR4 activation. (D) Lipid extracts from GF mouse
intestinal mucosa (GFimcm) inhibit BtLPS-dependent TLR4 activation. The results obtained with a combination of the agonist (BtLPS) and the lipid fractions
(SPFfeccm, SPFimcm, GFfeccm, or GFimcm) are representative of those from at least two independent experiments and were plotted as percent activation minus
the background standard deviation from triplicate determinations relative to that obtained with BtLPS alone minus the background, which was considered to
be 100% activation. Asterisks represent significant differences in NF-
B activation observed for BtLPS alone compared to that observed for BtLPS in combination
with the indicated lipid fraction (*, P 0.05; **, P 0.001; ***, P 0.0001; unpaired Student t tests).
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significantly vary from that of the feces of control mice and that
the extracts generated from these feces maintained their ability to
suppress TLR4 activation in response to B. thetaiotaomicron LPS
(see Fig. S6 and S7 in the supplemental material).
DSS promotes a marked shift in the intestinal microbial
composition that correlates with increased TLR4 activity. We
suspected that the increase in TLR4 activity of the feces of DSS-
treated mice obtained on day 7 of treatment (Fig. 6A) and the LPS
obtained from these feces (Fig. 6B) may be due to a change in the
microbial composition, which in turn might increase the abun-
dance of more potent LPS species. It is known that DSS alters the
intestinal microbial composition of mice (22) as well as increases
soluble TLR4 ligand activity in mouse feces (12). Therefore, the
microbial load of the intestinal and colonic contents derived from
either control SPF mice or DSS-treated mice on day 7 of treatment
was quantified by determining the cultivatable anaerobic bacteria
(Fig. 7). These data demonstrated that the cultivatable microbial
loads in both the intestine (Fig. 7A) and colon (Fig. 7B) differed
significantly between DSS-treated mice and SPF mice. Further-
more, analyses of the microbial composition by 16S rRNA se-
quencing additionally confirmed an increase in the proportion of
members of the family Enterobacteriaceae in the intestines (Fig.
7C) and colons (Fig. 7D) of DSS-treated mice, which is consistent
with the findings of Lupp et al. (22). We note that the variability in
the overall microbial composition observed in our study com-
pared to that observed in other studies likely arose due to the
FIG 4 Lipid fractions from SPF and GF mouse feces and intestinal mucosa display similar major mass ion species that correspond to cardiolipin isoforms.
Negative ion MALDI-TOF MS was performed to assess the predominant mass ions present in chloroform-methanol lipid extracts of the feces and intestinal
mucosa of SPF and GF mice. The atomic mass units assigned to the major peaks are indicated. (A to D) Major negative mass ions present in SPFfeccm (A), GFfeccm
(B), SPFimcm (C), and GFimcm (D). (E) Structure of the major cardiolipin [1,3-bis(3-sn-phosphatidyl)glycerol] species corresponding to the negative mass ions
present in GFfeccm, SPFfeccm, GFimcm and SPFimcm. R1 to R4, fatty acids residues attached to the side chain glycerol residues. The positions of the
1H NMR signals
for protons of side chain glycerol residues CH2OR1(4), CHOR2(3), and CH2OP(O) and for protons of the central glycerol CH2OP(O) and CHOH are shown in
Table 1. The side chain glycerol residues are indicated by dotted lines. intens., intensity; a.u., atomic mass units.
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method used to culture the isolates from the mouse microbiota
and mouse-to-mouse batch variability.
LPS in feces from DSS-treated mice and E. coli LPS are less
susceptible to TLR4 suppression by intestinal lipids. The obser-
vations that feces from DSS-treated mice showed increasing acti-
vation of TLR4 (Fig. 6), even though there was no change in the CL
content of the feces of DSS-treated mice (see Fig. S6 in the supple-
mental material), and that extracts of feces from DSS-treated mice
retained the ability to inhibit TLR4 activation by B. thetaiotaomi-
cron LPS (see Fig. S7 in the supplemental material) indicated that
the changed microbial composition of DSS-treated mice (Fig. 7)
produces LPS that is less susceptible to intestinal lipid and CL
inhibition. Consistent with this finding, it was found that fecal and
intestinal chloroform-methanol extracts from either SPF or germ-
free mice as well as purified CL exhibited a significantly reduced
ability to suppress TLR4 activation in response to LPS collected
from the feces of DSS-treated mice on day 7 of treatment com-
pared to their ability to suppress TLR4 activation in response to
LPS from control SPF mice (compare Fig. 8A to B and compare
Fig. 8C to D). To determine if the increase in the proportion of
members of the family Enterobacteriaceae (at the expense of the
Bacteroides sp.) could account for the TLR4 activation by feces
collected from DSS-treated mice on day 7 of treatment and their
LPS, we compared how effectively CL and lipid extracts sup-
pressed TLR4 activation by B. thetaiotaomicron and E. coli LPSs. It
was observed that both fecal and intestinal lipid extracts and CL
were significantly more effective at neutralizing TLR4 activation
in response to B. thetaiotaomicron LPS than at neutralizing TLR4
activation in response to E. coli LPS (compare Fig. 9A to B and
compare Fig. 9C to D).
These data provide novel evidence that feces from DSS-fed
FIG 5 CL and mouse fecal lipids antagonize LPS-dependent TLR4 activation
by a similar mechanism. The HEK293 cell-based luciferase assay was used to
assess recombinant TLR4 activation or endogenous IL-1R activation. (A) CL
inhibits BtLPS-dependent TLR4 activation. (B) CL does not inhibit IL-1-
dependent IL-1R activation. The results obtained with an agonist (LPS or
IL-1) combined with CL are representative of those from at least two inde-
pendent experiments and were plotted as percent activation minus the back-
ground  standard deviation from triplicate determinations relative to that
obtained with the agonist alone (LPS or IL-1) minus the background, which
was assigned a value of 100% activation. Asterisks represent significant differ-
ences in NF-
B activation observed for BtLPS alone compared to that ob-
served for BtLPS in combination with the indicated doses of CL (*, P 0.05;
***, P  0.0001; unpaired Student t tests). (C) CL, SPFfeccm, and GFfeccm
inhibit the ability of LPS to interact with LBP, CD14, and MD-2. (D) P. gingi-
valis LPS (PgLPS) inhibits the ability of LPS to interact with MD-2 but not LBP
or CD14. EcLPS with biotin alone or in combination with the indicated frac-
tions was allowed to form complexes with recombinant LBP, CD14, or MD-2.
Subsequently, the complexes were recovered by streptavidin-agarose-pull-
down assays, and the proteins bound to EcLPS with biotin were visualized by
Western blotting. The results are representative of those from at least two
independent experiments.
FIG 6 Feces and fecal LPS from DSS-fed mice fail to suppress TLR4 activation,
whereas feces and fecal LPS from conventionally fed mice do suppress TLR4
activation. Recombinant TLR4 activity was measured using a HEK293 cell-
based luciferase reporter assay. (A) The relative abilities of feces from mice
treated with DSS and collected on from day 1 of treatment (DSSfecd1) to day 7
of treatment (DSSfecd7) and feces from SPF mouse controls (SPFfeccontrol) to
activate TLR4 were compared. (B) The relative abilities of LPS derived from
the feces of DSS-treated mice on day 7 of treatment (DSSfecd7LPS) and LPS
derived from the feces of SPF mouse controls (SPFfeccontrolLPS) to activate
TLR4 were compared. The results are representative of those from at least two
independent experiments and were plotted as the mean fold induction 
standard deviation from triplicate determinations relative to that for the un-
stimulated control. Asterisks represent significant differences in NF-
B acti-
vation observed for feces from SPF mice compared to that observed for feces
from DSS-treated mice or significant differences in NF-
B activation observed
for LPS derived from the feces of SPF mouse controls compared to that ob-
served for LPS derived from the feces of DSS-treated mice on day 7 of treat-
ment (***, P 0.0001; unpaired Student t tests).
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mice exhibit a progressively increased proinflammatory potential
with respect to TLR4 signaling. The increase in TLR4 activity is not
due to the loss of CL or the inability to suppress TLR4 activation in
response to B. thetaiotaomicron LPS. Rather, the increase in the
TLR4 activity of the crude LPS preparation obtained from DSS-
treated mice on day 7 of treatment is consistent with a significant
increase in the proportion of members of the family Enterobacte-
riaceae, which contain a significantly more potent LPS that is less
susceptible to neutralization by the intestinal lipids found in
mouse feces.
To gain formal evidence that an excess of exogenously
added CL can suppress the LPS activity present in the feces of
DSS-treated mice on day 7 of treatment, purified CL was added
to the feces of DSS-treated mice on day 7 of treatment and
tested for the ability to stimulate TLR4. It was found that in-
creasing concentrations of exogenously added CL could effec-
tively reduce the TLR4 response in the feces of DSS-treated
mice on day 7 of treatment to near background levels (Fig. 9E).
These data strongly suggest that CL, when present in excess,
can reinforce the protective barrier established by the host to
limit interactions between the endogenous intestinal Gram-
negative microbiota and TLR4.
FIG 7 The intestinal anaerobic microbiota of DSS-fed mice displays a bacterial load and composition altered from those of the intestinal anaerobic
microbiota of conventionally fed mice. DSS promotes a pronounced shift in the anaerobic Gram-negative microbial composition of mouse feces and
intestinal contents. The intestinal and colon anaerobic bacterial loads and compositions of control SPF mice and DSS-fed mice (day 7) were determined.
(A) Intestines from DSS-treated mice mouse obtained on day 7 of treatment exhibit an increased anaerobic bacterial load compared to that of control SPF
mouse intestines. (B) Colons from DSS-treated mice obtained on day 7 of treatment exhibit a decreased anaerobic bacterial load compared to that of
control SPF mouse colons. (C) Gram-negative Enterobacteriaceae are more prevalent in intestines from DSS-treated mice mouse obtained on day 7 of treatment
than control SPF mouse intestines. (D) Gram-negative Enterobacteriaceae are more prevalent in colons from DSS-treated mice obtained on day 7 of treatment
than control SPF mouse intestines.
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DISCUSSION
It has recently become clear that the lipid A structures of LPS to
which intestinal tissue is exposed are significantly different in
healthy and diseased individuals (15, 16, 20, 21, 23). Specifically,
healthy individuals are exposed to significantly more LPS from the
family Bacteroidaceae than individuals with dysbiotic microbial
communities, where significant increases in the proportions of
members of the family Enterobacteriaceae are found (15, 22). For
example, obesity (15, 16), necrotizing enterocolitis in infants (43),
as well as ulcerative colitis and Crohn’s disease are all associated
with intestinal dysbiotic communities, all of which result in sig-
nificantly different lipid A structures in the intestinal lumen (9,
44). In this report, we describe a phospholipid-based barrier
found in the intestine which has the ability to discriminate be-
tween these two different types of LPS lipid A structures. Previous
reports have described both physical and spatial barriers which
preclude interactions between the intestinal lumen components
and the epithelial cell lining of intestinal tissue that are nonspe-
cific, in that they prevent a wide variety of different bacterial and
bacterial component interactions with intestinal tissue. For exam-
ple, IgA produced by the gut-associated lymphoid tissue has been
implicated in neutralizing the proinflammatory activity of the
commensal microbiota via interaction with bacterial surface mol-
ecules, including the O antigen of LPS (45). However, the intesti-
nal lipid barrier described here differs in two important aspects.
First, the barrier does not rely upon a physiospatial separation of
bacteria and their products from the luminal epithelium. Instead
it is mediated via a neutralization mechanism that depends upon
endogenous CL that is derived from the host intestinal epithelium
and that directly inhibits TLR4 signaling. Second, the barrier is
significantly more effective at inhibiting TLR4 activation in re-
sponse to the LPS that is found in healthy intestinal microbiomes
and that is typified by the LPS found in B. thetaiotaomicron rather
than members of the family Enterobacteriaceae, which is typified
by the LPS found in E. coli. This differential specificity could be
viewed as an intestinal surveillance mechanism which is able to
block LPS structures found in symbiotic microbial communities
and is overcome during episodes of dysbiosis.
The competitive inhibition studies described here demon-
strated CL inhibition of LPS binding at both LBP and CD14 in the
LBP–CD14 –MD-2/TLR4 activation pathway. CL was previously
shown to inhibit LPS activation of mononuclear cells presumably
by its structural similarity to compound 406, a lipid A structural
antagonist (38). Furthermore, it was shown that although other
host phospholipids were less potent than CL, they were able to
inhibit mononuclear cell LPS responses by targeting LBP, al-
though the mechanism was not elucidated (38). Since the chloro-
form-methanol extracts that inhibited LPS activation of TLR4
demonstrated similar levels of competitive inhibition of LBP and
CD14 binding and CL was a major component in those extracts, it
was concluded that CL and perhaps other phospholipids were
responsible for TLR4 inhibition. Studies in germfree mice re-
vealed that the source of the CL was the host and most likely arose
in the intestinal lumen by the turnover of intestinal epithelial cells
(39, 46). Indeed, studies have shown that intestinal commensal
bacteria (19, 39, 46) and, specifically, LPS can regulate epithelial
cell proliferation in a TLR4-dependent fashion in both health and
disease (47, 48).
In the present study, we employed the LPS derived from the
human gut symbiont B. thetaiotaomicron as a commensal symbi-
otic representative of the family Bacteroidaceae. To the best of our
knowledge, the LPS structures of commensal symbiotic Bacte-
roides spp. have not been well characterized, although they are
likely to have structures and, hence, endotoxic properties similar
FIG 8 Cardiolipin and mouse intestinal lipids inhibit SPFfecLPS-dependent TLR4 activation more potently than DSSfecd7LPS-dependent TLR4 activation.
Recombinant TLR4 activity was measured using a HEK293 cell-based luciferase reporter assay. (A) Abilities of CL and mouse fecal lipids to inhibit SPFfecLPS-
dependent TLR4 activation. (B) Abilities of CL and mouse fecal lipids to inhibit DSSfecd7LPS-dependent TLR4 activation. (C) Abilities of mouse intestinal mucosa
lipids to inhibit SPFfecLPS-dependent TLR4 activation. (D) Abilities of mouse intestinal mucosa lipids to inhibit DSSfecd7LPS-dependent TLR4 activation. The
results obtained with agonists (SPFfecLPS or DSSfecd7LPS) combined with antagonists (CL or chloroform-methanol lipid fractions of feces or intestinal mucosa)
are representative of those from at least two independent experiments and were plotted as percent activation minus the background standard deviation from
triplicate determinations relative to that for the agonists alone (SPFfecLPS or DSSfecd7LPS) minus the background, which was considered to be 100% activation.
Asterisks represent significant differences in NF-
B activation observed for SPFfecLPS or DSSfecd7LPS alone compared to the results for SPFfecLPS or DSSfecd7LPS
in combination with the indicated lipid fraction (*, P 0.05; **, P 0.001; ***, P 0.0001; ns, not significant; unpaired Student t tests).
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to those of B. thetaiotaomicron LPS. For example, the human sym-
bionts Bacteroides fragilis and B. thetaiotaomicron display similar
LPS structures as well as similar abilities to act as TLR4 agonists
(49). In contrast, LPS structures derived from related commensals
that are considered to be more pathogenic, such as the oral patho-
gen Porphyromonas gingivalis or the intestinal pathogen Bacte-
roides vulgatus, exhibit distinct structural properties and function
as very weak agonists or even antagonists at TLR4 (50, 51). The
selective inhibition of the family Bacteroidaceae-type LPS com-
pared to that of the family Enterobacteriaceae-type LPS by CL and
other phospholipids can be accounted for by lipid A structural
features which differ between members of these two bacterial fam-
ilies. FamilyEnterobacteriaceaeLPS lipid A structures demonstrate
higher binding affinities for the LBP–CD14 –MD-2/TLR4 activa-
tion pathway than family Bacteroidaceae lipid A structures (52).
Lipid A components that significantly alter binding and subse-
quent activation in the TLR4 activation pathway are the number
of phosphate groups and the number and length of fatty acids
found in the lipid A (53–55). For example, members of the family
Bacteroidaceae contain a lipid A that is monophosphorylated,
whereas members of the family Enterobacteriaceae contain a
diphosphorylated lipid A structure (56). The presence or absence
of mono- or diphosphorylated lipid A structures appears to be
highly conserved among members of the same bacterial family
(57, 58). In addition, it has recently been demonstrated that 733
independent intestinal isolates of members of the family Bacte-
roidaceae demonstrate antimicrobial peptide resistance which has
been correlated with a monophosphorylated lipid A structure (35,
57). In contrast, the lipid A in the family Enterobacteriaceae is
diphosphorylated and consists mostly of shorter-chain-length
fatty acids (58). Although other lipid A structural modifications
have been described for members of both of these families (59),
reflecting the well-known lipid A structural heterogeneity within a
bacterial species, the monophosphorylated and altered fatty acid
acylation patterns are two lipid A structural features that are fairly
uniform among family members (56, 60). Structure-activity stud-
ies examining these lipid A characteristics have shown that they
are associated with significantly less potent TLR4 activation (61).
Direct comparisons of the B. thetaiotaomicron and E. coli LPSs
have confirmed that the B. thetaiotaomicron LPS is 100 to 1,000
FIG 9 Cardiolipin and mouse intestinal lipids inhibit BtLPS-dependent TLR4 activation more potently than EcLPS-dependent TLR4 activation. Recombinant
TLR4 activity was measured using a HEK293 cell-based luciferase reporter assay. (A) Abilities of CL and mouse fecal lipids to inhibit BtLPS-dependent TLR4
activation. (B) Abilities of CL and mouse fecal lipids to inhibit EcLPS-dependent TLR4 activation. (C) Abilities of mouse intestinal mucosa lipids to inhibit
BtLPS-dependent TLR4 activation. (D) Abilities of mouse intestinal mucosa lipids to inhibit EcLPS-dependent TLR4 activation. (E) The relative abilities of
exogenous mouse fecal lipids and exogenous CL to inhibit DSSfecd7-dependent TLR4 activation were measured. The results obtained with agonists (BtLPS,
EcLPS, or DSSfecd7) combined with antagonists (CL or chloroform-methanol lipid fractions of feces or intestinal mucosa) are representative of those from at least
two independent experiments and were plotted as percent activation minus the background standard deviation from triplicate determinations relative to that
for the agonists alone minus the background, which was considered to be 100% activation. Asterisks represent significant differences in NF-
B activation
observed for BtLPS, EcLPS, or feces from DSS-treated mice alone compared to that for BtLPS, EcLPS, or feces from DSS-treated mice in combination with the
indicated lipid fraction (*, P 0.05; **, P 0.001; ***, P 0.0001; unpaired Student t tests).
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times less potent than the E. coli LPS in its ability to elicit TLR4
activation in the concentration range of fecal LPS concentrations
tested in the present study (1 to 10 ng/ml) (49). Reasons for the
decreased potency of B. thetaiotaomicron LPS compared to that of
the Enterobacteriaceae LPS include significantly lower affinities for
binding to both LBP and CD14 (52), two accessory proteins which
greatly increase the potency of TLR4. In addition, the degree and
amount of lipid A phosphorylation as well as the number and
types of fatty acids can influence TLR4 potency after LPS has been
delivered to the MD-2/TLR4 receptor complex (54). Therefore,
dysbiotic shifts in the intestinal microbiome which result in sig-
nificant increases in the proportions of members of the family
Enterobacteriaceae are associated with more potent lipid A struc-
tures, which can render intestinal tissue more susceptible to TLR4
activation simply by reducing the amount of LPS necessary to
potently activate TLR4. In fact, this has recently been demon-
strated in a Rag1/ mouse model of colitis (24). It was demon-
strated that LPS with higher levels of TLR4 activity was a key
determinant of whether mice develop colitis in the adaptive trans-
fer model. A recent review predicted that significantly more po-
tent LPS contributes to inflammation associated with inflamma-
tory bowel disease in dysbiotic communities and discussed the
ramifications of dysbiotic shifts in polymicrobial communities
(56).
The maintenance of intestinal homeostasis can be accom-
plished in an LPS-rich intestinal lumen when the majority of the
lipid A structures are less able to enter the LBP–CD14 –MD-2/
TLR4 activation pathway due to the presence of excess host CL
and phospholipids. It has recently been shown that less potent
monophosphorylated family Bacteroidaceae-type lipid A struc-
tures are maintained in the intestinal lumen, presumably as a
mechanism to maintain intestinal homeostasis (57). In addition,
it has been demonstrated that host intestinal alkaline phosphatase,
which renders diphosphorylated family Enterobacteriaceae-type
LPS, which is a potent activator of TLR4, similar to less potent
monophosphorylated family Bacteroidaceae-type LPS, can pre-
vent metabolic syndrome in mice through the detoxification of
LPS (8). Shed CL as well as the intestinal phospholipid barrier may
represent another mechanism by which monophosphorylated
family Bacteroidaceae-type LPS in the intestinal lumen due to sig-
nificantly lower binding to LBP and transfer to CD14 (52) is neu-
tralized before engagement of TLR4. In addition, both LBP and
CD14 are made by intestinal epithelial cells (62, 63), and evidence
that they contribute to intestinal homeostasis has been reported
(64, 65). Furthermore, modulation of TLR4 activity by LPB may
have some clinical utility in treating necrotizing enterocolitis (66).
Indeed, it might also be expected that both the bile salt (67) and
phospholipid (68) barrier would display selective inhibition of the
family Bacteroidaceae-type LPS rather than the family Enterobac-
teriaceae-type LPS for the same reasons that CL was shown here to
be a more effective family Bacteroidaceae-type LPS blocker at LBP
and CD14. Consistent with this, the intestinal phospholipid bar-
rier has been shown to be altered in ulcerative colitis, and this may
contribute to increased LPS activation (1). Furthermore, the crys-
tal structure of the MD-2/TLR4 LPS receptor also predicts that the
family Bacteroidaceae-type LPS could be more effectively blocked
from active engagement due to the loss of a phosphate group (69).
The relationship between the lipid A structure and TLR4 activa-
tion as it relates to the innate host response has previously been
addressed by Munford and Varley (60); however, the less potent
TLR4 activation displayed by the family Bacteroidaceae LPS, rep-
resenting a significant factor contributing to the maintenance of
intestinal homeostasis, was not considered at that time.
Supplementation of the inflammatory fecal extracts from DSS-
treated mice with excess CL significantly reduced TLR4 activation,
suggesting that the addition of CL to the diet may reduce the
inflammation associated with dysbiotic communities. Indeed, it
has been shown that dietary gangliosides can reduce proinflam-
matory signaling in individuals with IBD (70). The work pre-
sented here suggests that a novel mechanism by which host CL and
the other phospholipids may modulate intestinal inflammation is
by inhibition of the LPS entering the LBP–CD14 –MD-2/TLR4
pathway.
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